A Phase 1 Study of ABT-869 in Subjects With Solid Tumors
An Open Label, Phase I Study Evaluating Pharmacokinetics, Safety, and Tolerability of ABT-869 in Subjects With Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Subjects aged from 20 to 75 years and ECOG PS of 0-2 at screening.
- Subject must have a solid tumor that is refractory to standard therapies or for which a standard effective therapy does not exist.
- The subject must have adequate bone marrow, renal and hepatic function.
- Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation and up to six months following completion of therapy.
- The subject must voluntarily sign and date an informed consent.
Exclusion Criteria
- The subject currently exhibits symptomatic or intervention indicated CNS metastasis.
- The subject has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic or any investigational therapy within 4 weeks of enrollment or has not fully recovered from toxicity resulting from past treatment(s) that affects the assessments in this study at the enrollment.
The subject with the following conditions during screening assessment.
- proteinuria CTC grade > 1 as measured by urinalysis and 24 hour urine collection
- diastolic blood pressure (BP) > 95 mmHg; or systolic blood pressure (BP) > 150 mmHg
- a history of or currently exhibits clinically significant cancer related events of bleeding
- LV Ejection Fraction < 50%
- received a cumulative dose of Anthracycline > 360 mg/m2 for treatment of cancer
- receiving therapeutic anticoagulation therapy
- having fractures except for chronic bone lesion due to bone metastases
- The subject exhibits evidence of other clinically significant uncontrolled condition(s).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group 1
Dose escalation from Open label 0.05 to 0.25 mg/kg once a day dosing for 21 days
|
2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression.
For more information, please see Arm Description.
|
|
Experimental: Group 2
Open label 0.10 mg/kg once a day dosing after safety evolution of Group 1
|
2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression.
For more information, please see Arm Description.
|
|
Experimental: Group 3
Open label 0.20 mg/kg once a day dosing after safety evolution of Group 2
|
2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression.
For more information, please see Arm Description.
|
|
Experimental: Group 4
Open label 0.25 mg/kg once a day dosing after safety evolution of Group 3
|
2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression.
For more information, please see Arm Description.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety tolerability assessment
Time Frame: Weekly assessment for 3 weeks then every 3 weeks or more frequently as needed
|
Weekly assessment for 3 weeks then every 3 weeks or more frequently as needed
|
|
Dose limiting toxicity determination
Time Frame: Weekly assessment for the first 3 weeks
|
Weekly assessment for the first 3 weeks
|
|
Pharmacokinetic profile evaluation
Time Frame: Day 1 and Day 15
|
Day 1 and Day 15
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Preliminary tumor response
Time Frame: Every 6 week
|
Every 6 week
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- M10-227
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.